The Serum Institute of India (SII) is doing its best to increase production of the COVID-19 vaccine Covishield to meet domestic demand, Adar Poonawalla said Saturday. In response to a tweet from JSW Group Chairman Sajjan Jindal, Poonawalla said the vaccine major is doing its best to prioritize the introduction of vaccines into the Indian market.
“Yes @ sajjanjindal, @ SerumInstIndia are doing their best to increase production and launch new vaccines based on India’s priorities. Working with this pandemic fight, India’s medical oxygen needs We are grateful for @ TheJSWGroup’s efforts to meet this requirement, “Poonawalla said in a tweet.
Earlier Sajjan Jindal tweeted while tagging SII, Poonawalla, Bharat Biotech, and their managing director Krishna Ella. “The only way to get # FightAgainstCOVID19 in India is to vaccinate everyone. It’s great to see @ SerumInstIndia @ adarpoonawalla and @ BharatBiotech @ krishnaella increasing their capacity.
Both SII and Bharat Biotech are at the forefront of supplying the COVID-19 vaccine domestically, despite the second wave of pandemics continuing to devastate various states.
Read all the latest news, latest news, coronavirus news here
The Serum Institute is doing its best to increase production of the Covid-19 vaccine, says Adar Poonawalla.
Source link The Serum Institute is doing its best to increase production of the Covid-19 vaccine, says Adar Poonawalla.